First-line immune-chemotherapy combination for squamous NSCLC is already a reality

Lizza E. L. Hendriks*, Jessica Menis, Jordi Remon

*Corresponding author for this work

Research output: Contribution to journalEditorialAcademicpeer-review

2 Downloads (Pure)
Original languageEnglish
Pages (from-to)819-823
Number of pages5
JournalTranslational Lung Cancer Research
Volume9
Issue number3
DOIs
Publication statusPublished - Jun 2020

Keywords

  • CELL LUNG-CANCER
  • OPEN-LABEL
  • PEMBROLIZUMAB

Cite this